Nafasy.AI

There are over 15 billion cases of respiratory infections globally each year, yet tracking and early detection remain woefully insufficient. Traditional diagnostic methods take hours to days for results, cost patients significantly, and require clinical infrastructure that is inaccessible to most of the world's population. In MENA and developing regions, respiratory diseases are further compounded by poor air quality, dust, mass gatherings like Hajj, and high population density at global transit hubs. The result is chronic underreporting, delayed treatment, and preventable spread of infectious disease.

Nafasy.AI has been set up to advance a patented, smartphone-based AI screening tool co-developed by the teams at Virufy and the University of Washington. The technology analyses cough sound patterns to detect respiratory diseases in minutes, at zero cost to the user. The tool has achieved 84% sensitivity and specificity, is backed by a proprietary dataset of 256,600 patient cough and speech samples paired with PCR results, and has been validated through a US Department of Health (BARDA) contract. Unlike conventional testing, this rapid and cost-effective solution requires no equipment, no clinical setting, and no trained personnel, making it instantly deployable anywhere there is a smartphone.